James Murrough, MD
- ASSISTANT PROFESSOR | Psychiatry
- ASSISTANT PROFESSOR | Neuroscience
Dr. James Murrough is Assistant Professor of Psychiatry and Neuroscience and Director of the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai. Dr. Murrough received his Bachelor of Science in neuroscience and behavioral biology from Emory University in Atlanta and his Medical degree from Tufts University School of Medicine in Boston. He completed his residency training in Psychiatry at Mount Sinai and a research fellowship in experimental therapeutics and clinical neuroscience in mood disorders, also at Mount Sinai. Dr. Murrough received a Career Development Award from NIMH and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. Dr. Murrough conducts clinical and translational research focused on the development of novel therapeutics and on characterizing alterations in neurocircuitry underlying mood and anxiety disorders. His research includes functional brain imaging approaches to discover the mechanisms of rapidly acting antidepressants. The overall goal of this program of research is to increase the understanding of mechanisms of illness in these disorders in order to identify novel, more effective treatments for patients.
Key Words: depression, bipolar disorder, post traumatic stress disorder, psychopharmacology, antidepressants, functional neuroimaging
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
Psychiatry, American Board of Psychiatry and Neurology
- Magnetic resonance imaging (MRI)
- Panic Disorder
Residency, Psychiatry, Mount Sinai Hospital
- Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment Resistant Depression
The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of k...
- An fMRI Study of Ketamine in Treatment-Resistant Depression
The purpose of this study is to investigate the antidepressant mechanism of action of ketamine in patients with treatment-resistant major depression (TRD) using functional magnetic resonance imaging (fMRI). Ketamine is a N-methyl-D-aspartate (NMDA) glutamate receptor antagonis...
- A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder
The purpose of this study is to test the safety tolerability and efficacy of ezogabine as a new antidepressant treatment for individuals suffering from major depressive disorder. Ezogabine is a potassium (K+) KCNQ2-selective channel potentiator and is believed to improve mood ...
- Intranasal Administration of Neuropeptide Y in PTSD
The purpose of this study is to evaluate the antidepressant and anti-anxiety effect of intranasal administration of neuropeptide Y (NPY) for patients with post-traumatic stress disorder (PTSD). NPY is not approved for the treatment of PTSD and is considered experimental in thi...
- A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of ketamine in subjects with treatment-resistant depression
The primary objective of this study is to evaluate the efficacy of intravenous (IV) ketamine administered 2 or 3 times a week for 4 weeks for the treatment of treatment-resistant depression. The study involves 4 weeks of either active ketamine or placebo. After 2 weeks of non-...
- A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic Antidepressant in Adults with Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of sirukumab as an adjunctive treatment to antidepressant therapy (monoaminergic antidepressant). Sirukumab will be administered as a subcutaneous injection three times during the 12-week double blind treatment period.
Murrough JW, Mathew SJ. Overcoming antidepressant treatment resistance: focus on glutamate. Modern Trends in Pharmacopsychiatry; 27.
Murrough JW, Mathew SJ. Neurochemical Imaging in Anxiety Disorders. Neuropsychiatric Imaging;.
Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P, Levine SM, Mathew SJ, Shungu DC. Increased Ventricular Cerebrospinal Fluid Lactate in Chronic Fatigue Syndrome. Part II: Comparison with Major Depressive Disorder by 1H MRS at 3.0 Tesla. NMR Biomedicine 2010; 23: 643-650.
Murrough JW, Henry S, Hu J, Gallezot JD, Planeta-Wilson B, Neumaier JF, Neumeister A. Reduced ventral striatal/ventral pallidal serotonin(1B) receptor binding potential in major depressive disorder. Psychopharmacology (Berl) 2010 May;.
aan het Rot M, Collins KA, Murrough JW, Perez A, Reich DL, Charney DS, Mathew SJ. Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression. Biol Psychiatry 2010; 67: 139-145.
Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Garakani A, Reich DL, Charney DS. Riluzole for Relapse Prevention Following Intravenous Ketamine in Treatment-Resistant Depression: A Pilot Randomized, Placebo-Controlled Study. Int J Neuropsychopharm 2010; 13: 71-82.
New AS, Fan J, Murrough JW, Liu X, Liebman RE, Guise KG, Tang CY, Charney DS. An Functional Magnetic Resonance Imaging Study of Deliberate Emotion Regulation in Resilience and Posttraumatic Stress Disorder. Biol. Psychiatry 2009; 66: 656-664.
Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ. Amino Acid Neurotransmitters in the Occipital and Anterior Cingulate Cortices: Relationship to Treatment-Resistance in Major Depressive Disorder. Biol Psychiatry 2009; 65: 792-800.
Epstein J, Pan H, Kocsis JH, Yang Y, Butler T, Chusid J, Hochberg H, Murrough J, Strohmayer E, Stern E, Silbersweig DA. Lack of Ventral Striatal Response to Positive Stimuli in Depressed Versus Normal Subjects. Am J Psychiatry 2006; 163: 1784-1790.
Murrough JW, Boss-Williams KA, Emery MS, Bonsall RW, Weiss JM. Depletion of Brain Norepinephrine Does Not Reduce Spontaneous Ambulatory Activity of Rats in the Home Cage. Brain Res 2000; 883: 125-130.